Xenon Pharmaceuticals (XENE) Restructuring Costs (2024 - 2026)

Xenon Pharmaceuticals (XENE) has 3 years of Restructuring Costs data on file, last reported at $7.8 million in Q1 2026.

• Restructuring Costs for Q1 2026 came in at $7.8 million, up 41.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.1 million (up 36.52% YoY), and the FY2025 annual result was $26.8 million, up 29.71% from the prior year.
• Restructuring Costs declined to $7.8 million in Q1 2026 per XENE's latest filing, from $8.5 million in the prior quarter.
• Over five years, Restructuring Costs peaked at $8.5 million in Q4 2025 and troughed at $4.6 million in Q3 2024.
• A 3-year average of $6.1 million and a median of $5.7 million in 2024 frame the typical range for Restructuring Costs.
• On a YoY basis, Restructuring Costs climbed as much as 53.99% in 2025 and fell as far as 6.27% in 2025.
• A 3-year view of Restructuring Costs shows it stood at $5.5 million in 2024, then soared by 53.99% to $8.5 million in 2025, then declined by 8.59% to $7.8 million in 2026.
• Business Quant data shows XENE's Restructuring Costs at $7.8 million in Q1 2026, $8.5 million in Q4 2025, and $6.7 million in Q3 2025.